CClinicalTrials.gg
Sign In
Active, not recruitingNCT04944979KIDCARES10Updated May 29, 2026

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)

A Phase 3 interventional study of Kedrion IVIG 10% in Primary Immunodeficiency Disease, sponsored by Kedrion S.p.A.. Active, not recruiting at 21 sites in 6 countries. Open to participants aged 2 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Kedrion S.p.A. · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
2 Years to 16 Years
Sex
All
01

Study summary

The purpose of this study is to assess efficacy, safety and pharmacokinetics of Kedrion Immunoglobulin 10% (KIg10) in pediatric patients with Primary Immunodeficiency Disease (PID).

02

Conditions studied

  • Primary Immunodeficiency Disease

Keywords

  • Immunoglobulin
  • Kedrion IVIG 10%
  • IgG Antibodies
  • Agammaglobulinemia
  • Hypogammaglobulinemia
  • Pediatric
03

In context

Primary Immunodeficiency Diseases

199 studies on the registry are indexed under Primary Immunodeficiency Diseases; 46 are open to participants now.

This study's planned enrollment of 30 is below the median of 37 across 121 interventional studies indexed under Primary Immunodeficiency Diseases.

Browse Primary Immunodeficiency Diseases studies →

Lead sponsor

Kedrion S.p.A. is the lead sponsor of 10 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Written informed consent/assent obtained from the patient and his/her parent(s) or legally acceptable representative indicating that they understand the purpose of and procedures required for the study and are willing to participate in it.

  2. Confirmed clinical diagnosis of a PID as defined by 2017 International Union of Immunological Societies (IUIS) Phenotypic Classification for Primary Immunodeficiencies (Bousfiha A, 2018 - and subsequent revisions) and The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity (Seidel MG et al., 2019 - and subsequent revisions) and requiring treatment with IVIg. Documented agammaglobulinemia (defined as the total absence of one or more classes of antibodies) or hypogammaglobulinemia (defined as low levels of one or more classes [i.e., at least 2 standard deviations under the mean level per age]).

    (NOTE: IVIg treatment is generally requested in the absence of IgG independently from whether other antibodies are absent).

  3. Male or female, age from 2 up to \< 16 years, at the time of screening.

  4. Received 200 to 800 mg/kg of a commercially available IVIg therapy in the range of 21- or 28-day intervals (±3 or ±4 days, respectively) for at least 3 infusions prior to screening.

    (NOTE: Other IVIgs will be prohibited after ICF signature and until study end, week 51/52).

  5. At least 2 documented IgG trough levels while receiving an IVIg, of ≥ 6 g/L obtained at 2 infusions within 12 months (1 must be within 6 months) prior to ICF signature.
  6. Patient and his/her parent(s)/legal guardian(s) are willing to comply with all requirements of the protocol.

  7. Females of child-bearing potential with a negative pregnancy test (serum or urine) and who agree to employ adequate birth control measures during the study, such as:

    1. sexual abstinence, to be evaluated in relation to the preferred and usual lifestyle of the subject;
    2. male or female condom with or without spermicide;
    3. cap, diaphragm or sponge with spermicide;
    4. progestogen-only oral hormonal contraception, if already used in the past on medical prescription.

    Adequate birth control measures should be maintained throughout the study under parental control.

  8. Authorization to access personal health information.
  9. Patients previously participating in a clinical trial with another experimental IVIg may be enrolled if they have received stable commercially available IVIg therapy for at least 3 infusions (21 or 28 days) prior to screening.
  10. Patients currently on treatment with any subcutaneous immunoglobulin (SCIG) can be enrolled if they are switched to stable commercially available IVIg therapy for at least 3 infusions (21 or 28 days) prior to screening.
  11. Males or females with a body weight greater than or equal to 15 kg (≥ 15 kg).

Exclusion criteria

Exclusion Criteria:

  1. Newly diagnosed PID and naïve to IgG replacement therapy.
  2. Dysgammaglobulinemia (defined as a deficiency in one or more classes of antibodies, but not severe enough to require substitutive therapy) or isolated IgG subclass deficiency, or profound primary T cell deficiency (defined as the absence or severe reduction of T lymphocytes [CD3+ \< 300 cell/mm3] and an absent or particularly low proliferative response [10% of the lower normal range] to phytohaemagglutinin P [PHA]).
  3. History of severe or serious reactions or hypersensitivity to IVIg or other injectable forms of IgG.
  4. History of thrombotic events including deep vein thrombosis, cerebrovascular accident, pulmonary embolism, transient ischemic attacks, or myocardial infarction, as defined by at least 1 event in patient's lifetime.
  5. IgA deficiency with documented antibodies to IgA.
  6. Received blood products that have not undergone viral inactivation measures within 12 months prior to ICF signature.
  7. Significant protein losing enteropathy, nephrotic syndrome, or lymphangiectasia.
  8. An acute infection as documented by culture or diagnostic imaging and/or a body temperature ≥38.5 °C (≥101.3 °F) within 7 days prior to screening.
  9. Acquired immunodeficiency syndrome (AIDS) and/or hepatitis B/C active disease at ICF signature.
  10. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 times of the upper limit of normal for the laboratory designated for the study.
  11. Using an implanted venous access device.
  12. Moderate or severe anemia, defined according to patient's age as shown in the following table (World Health Organization, 2011) or persistent severe neutropenia (≤ 500 neutrophils per mm3) or persistent lymphopenia of less than 500 cells per microliter.
  13. A severe chronic condition such as renal failure [defined as abnormalities in kidney structure or function that are present for more than 3 months and have health implications. The disease is classified on the basis of cause and category of glomerular filtration rate (GFR) (G1 to G5) and albuminuria (A1 to A3) (KIDIGO, 2017). See the following table], congestive heart failure (New York Heart Association III/IV), cardiomyopathy, cardiac arrhythmia associated with thromboembolic events (e.g., atrial fibrillation), unstable or advanced ischemic heart disease, hyperviscosity, or any other condition that the Investigator believes is likely to interfere with evaluation of the study drug or with satisfactory conduct of the trial.
  14. History of a malignant disease other than properly treated carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin within 24 months prior to ICF signature.
  15. History of pharmacoresistant epilepsy or multiple episodes of migraine (defined as at least 1 episode within 6 months of ICF signature) not controlled by medication.

  16. Patient must not be receiving the following medication from at least 30 days prior to ICF signature:

    1. Steroids, inhaled, oral or parenteral, at a daily dosage of ≥ 0.15 mg/kg/day of prednisone or equivalent).
    2. Other immunosuppressive drugs (including monoclonal antibodies) or chemotherapy.
  17. Females who are pregnant, breast feeding or planning a pregnancy during the course of the study. Women who become pregnant during the study will be withdrawn from the study.
  18. Participated in another clinical study within 30 days prior to ICF signature.
  19. Active drug or alcohol abuse or history of drug or alcohol abuse within the 6 months before screening.
  20. Direct relative of an employee of the CRO, the study site, or Kedrion.
  21. Previously treated under this protocol.
  22. Unable to provide informed consent.
  23. Patients with any condition which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives or the patient's participation in this trial.
  24. Patients with Hypersensitivity to the active substance or to any of the excipients.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Experimental: Kedrion IVIG 10%

    Participants will receive intravenous infusion of Kedrion IVIG 10% at a dose of 200 to 800 milligram per kilogram (mg/kg) body weight every 21 or 28 days for period of 48 weeks.

    Biological: Kedrion IVIG 10%

Interventions

  • BiologicalKedrion IVIG 10%

    Kedrion intravenous immunoglobulin (IVIg) 10%

06

What researchers measure

Primary outcomes

  1. Incidence Rate of Acute Serious Bacterial Infections

    Incidence rate (i.e., the mean number of acute serious bacterial infections per patientyear) of acute serious bacterial infections (bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, visceral abscess, osteomyelitis/septic arthritis) according to pre-specified criteria).

    Time frame: From Baseline (Day 1) up to week 51/52

Secondary outcomes

  1. Serum Immunoglobulin G (IgG) trough levels

    Time frame: Before each infusion of KIg10 and at the study termination visit (Week 51/52)

  2. Immunoglobulin G (IgG) subclasses levels (IgG1, IgG2, IgG3, IgG4)

    Time frame: Before infusions 1, 5, 9 and 13 for the 28-day infusion schedule, and before infusions 1, 7, 11 and 17 for the 21-day infusion schedule

  3. Frequency of patients with total Immunoglobulin G (IgG) below 6 g/L

    Time frame: Day 1 up to week 51/52

  4. Anti-tetanus toxoid antibody level

    The quantitative evaluation will be reported

    Time frame: Before infusions 1, 5, 9 and 13 for the 28-day infusion schedule and before infusions 1, 7, 11 and 17 for the 21-day infusion schedule

  5. Anti-pneumococcal capsular polysaccharide antibody level

    The quantitative evaluation will be reported

    Time frame: Before infusions 1, 5, 9 and 13 for the 28-day infusion schedule and before infusions 1, 7, 11 and 17 for the 21-day infusion schedule

  6. Anti-measles antibody level

    The quantitative evaluation will be reported

    Time frame: Before infusions 1, 5, 9 and 13 for the 28-day infusion schedule and before infusions 1, 7, 11 and 17 for the 21-day infusion schedule

  7. Anti-Haemophilus influenza type b antibody level

    The quantitative evaluation will be reported

    Time frame: Before infusions 1, 5, 9 and 13 for the 28-day infusion schedule and before infusions 1, 7, 11 and 17 for the 21-day infusion schedule

  8. Incidence rate (i.e., the mean number per patient-year) of any infection other than acute serious bacterial infections

    Information reported by participant/participant's parent(s)/legal guardian(s) in the Patient Diary, provided starting from the first infusion.

    Time frame: From day 1 to week 51/52

  9. Duration of any infection other than acute serious bacterial infections

    Information reported by participant/participant's parent(s)/legal guardian(s) in the Patient Diary, provided starting from the first infusion.

    Time frame: From day 1 to week 51/52

  10. Incidence rate (i.e. the mean number per patient-year) of fever episodes

    Information reported by participant/participant's parent(s)/legal guardian(s) in the Patient Diary, provided starting from the first infusion.

    Time frame: From day 1 to week 51/52

  11. Duration of fever episodes

    Information reported by participant/participant's parent(s)/legal guardian(s) in the Patient Diary, provided starting from the first infusion.

    Time frame: From day 1 to week 51/52

  12. Overall hospitalization days

    Information reported by participant/participant's parent(s)/legal guardian(s) in the Patient Diary, provided starting from the first infusion.

    Time frame: From day 1 to week 51/52

  13. Days of hospitalizations due to infection

    Information reported by participant/participant's parent(s)/legal guardian(s) in the Patient Diary, provided starting from the first infusion.

    Time frame: From day 1 to week 51/52

  14. Incidence rate (i.e. the mean number per patient-year) of patient on antibiotics for the treatment of any kind of infection

    Information reported by participant/participant's parent(s)/legal guardian(s) in the Patient Diary, provided starting from the first infusion.

    Time frame: From day 1 to week 51/52

  15. Duration of patients on antibiotics for the treatment of any kind of infection

    Information reported by participant/participant's parent(s)/legal guardian(s) in the Patient Diary, provided starting from the first infusion.

    Time frame: From day 1 to week 51/52

  16. Days of missed work/school/other major activities due to infections

    Information reported by participant/participant's parent(s)/legal guardian(s) in the Patient Diary, provided starting from the first infusion.

    Time frame: From day 1 to week 51/52

  17. Pediatric Quality of Life Inventory (Pedsql) Score

    The PedsQL™ Measurement Model is a modular approach to measuring health-related QoL in healthy children and adolescents and those with acute and chronic health conditions. The 23-item PedsQL™ Generic Core Scales were designed to measure the core dimension of health as delineated by the World Health Organization, as well as role (school) functioning. The total scale score (23 items) consists of Physical health summary score (8 items) and Psychosocial health summary score (15 items). Physical health summary includes Physical Functioning (8 items) and Psychosocial health summary score includes Emotional Functioning (5 items), Social Functioning (5 items) and School Functioning (5 items). The overall range for PedsQL scores is 0 to 100, with a higher score indicating better quality of life.

    Time frame: At baseline, week 24, and study termination visit

  18. Number of Adverse Events (%) and proportion of patients experiencing at least one Adverse Event (AE)

    Time frame: From Baseline (Day 1) up to Week 51/52

  19. Number of Serisous AEs (%) and proportion of patients experiencing at least one Serious Adverse Event (SAE)

    Time frame: From Baseline (Day 1) up to Week 51/52

  20. Number of related infusion AEs (%) occurring during infusion or within 1, 24, and 72 hours after the end of infusion, and proportion of patients experiencing at least one related infusion AE. at least 1 of such related infusion AE.

    Time frame: From Baseline (Day 1) up to Week 51/52

  21. The proportion and number of KIg10 infusions for which the infusion rate is decreased due to Adverse Events.

    Time frame: From Baseline (Day 1) up to Week 51/52

  22. Number and proportion of infusions with one or more infusion (temporally-associated) Adverse Event.

    Time frame: From Baseline (Day 1) up to Week 51/52

  23. Number of Participants with Changes from Baseline Values in Vital Signs, Physical Examinations, Safety Laboratory Tests (hematology, serum chemistry and urinalysis).

    Number of participants with changes from baseline in vital signs (including blood pressure, heart rate and temperature); Physical examination (including evaluation of all body systems, body weight, height and Tanner Staging); Safety Laboratory Tests (including hematology, serum chemistry, and urinalysis) will be reported.

    Time frame: Up to Week 51/52

  24. The proportion and number of patients with a positive Coomb's test

    Time frame: Following infusion 7 for the 28-day infusion schedule and infusion 9 for the 21-day infusion schedule

  25. The proportion and number of patients with a positive urine hemosiderin test

    Time frame: Following infusion 7 for the 28-day infusion schedule and infusion 9 for the 21- day infusion schedule

  26. Serum haptoglobin level

    Time frame: Following infusion 7 for the 28-day infusion schedule and infusion 9 for the 21-day infusion schedule.

  27. Serum Total Immunoglobulin G (IgG) levels, IgG Subclasses Levels, and Selected Specific Antibody Levels

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  28. Plasma Concentration - Time Curve Of Total Immunoglobulin G (IgG)

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  29. Elimination Half-Life (t1/2) of Total Immunoglobulin G (IgG)

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  30. Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Total Immunoglobulin G (IgG)

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  31. Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUC[0-inf]) of Total Immunoglobulin G (IgG)

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  32. Volume of Distribution of Total Immunoglobulin G (IgG)

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  33. Maximum Observed Plasma Concentration (Cmax) Of Total IgG

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  34. Time to Reach the Maximum Plasma Concentration (Tmax) of Total Immunoglobulin G (IgG)

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  35. Elimination Rate Constant of Total Immunoglobulin G (IgG)

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  36. Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-Tau) of Total Immunoglobulin G (IgG)

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  37. Plasma Concentration-Time Curve Of Specific Immunoglobulin G (IgG) Antibodies

    The quantitative evaluation of the anti-Tetanus toxoid, anti-pneumococcal capsular polysaccharide, anti-Haemophilus influenza type B and anti-measles antibodies level will be reported

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  38. Elimination Half-Life (t1/2) of Specific IgG Antibodies

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  39. Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUC(0-T)) of Specific Immunoglobulin G (IgG) Antibodies

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  40. Volume Of Distribution of Specific Immunoglobulin G (IgG) Antibodies

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  41. Maximum Observed Plasma Concentration (Cmax) of Specific Immunoglobulin G (IgG) Antibodies

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  42. Time to Reach the Maximum Plasma Concentration (Tmax) of Specific Immunoglobulin G (IgG) Antibodies

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  43. Elimination Rate Constant of Specific Immunoglobulin G (IgG) Antibodies

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  44. Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC[0-inf]) of Specific Immunoglobulin G (IgG) Antibodies

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

  45. Area Under the Concentration-Time Curve From Time Zero up to Time Tau (AUC0-Tau) of Specific Immunoglobulin G (IgG) Antibodies

    Time frame: Before and after infusion 5 (28-day infusion schedule) or infusion 7 (21-day infusion schedule)

07

Study locations

21 sites
  • Benioff Children&#39;s Hospital - Mission Bay
    San Francisco, California 94158, United States
  • IMMUNOe Health and Research Centers
    Centennial, Colorado 80112, United States
  • Johns Hopkins All Children's Hospital
    St. Petersburg, Florida 33701, United States
  • Velocity Clinical Research - MedPharmics - Lafayette
    Lafayette, Louisiana 70508, United States
  • Louisiana State University Shreveport
    Shreveport, Louisiana 71103, United States
  • Duke Children's Hospital & Health Center
    Durham, North Carolina 27706, United States
  • Asthma and Allergy Center - Toledo
    Toledo, Ohio 43617, United States
  • Vital Prospects Clinical Research Institute PC
    Tulsa, Oklahoma 74136, United States
  • Dél-Pesti Centrumkórház - Országos Hematológiai És Infektológiai Intézet
    Budapest, Hungary
  • SST Spedali Civili di Brescia
    Brescia, Italy
  • Azienda Ospedaliero-Universitaria - Ospedale Pediatrico Meyer
    Florence, Italy
  • I.R.C.C.S. Istituto Giannina Gaslini
    Genova, Italy
  • Fondazione IRCCS Ca&#39; Granda Ospedale Maggiore Policlinic
    Milan, Italy
  • Azienda Ospedaliera Universitaria &#34;Federico II&#34;
    Naples, Italy
  • Fondazione Policlinico Tor Vergata
    Roma, Italy
  • IRCCS Ospedale Pediatrico Bambino Gesù
    Roma, Italy
  • Centro Hospitalar Lisboa Central - Hospital Dona Estefânia
    Lisbon, Portugal
  • Centro Hospitalar Universitário do Porto - Hospital Santo António
    Porto, Portugal
  • Children&#39;s City Clinical Hospital No. 9 named after G.N. Speransky, Moscow City Health Department
    Moscow, Russia
  • Dmitry Rogachev National Medical Research Center for Pediatric Hematology, Oncology and Immunology
    Moscow, Russia
  • Národný ústav detských chorôb (National Institute of Pediatric Diseases)
    Bratislava, Slovakia
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04944979
Lead sponsor
Kedrion S.p.A.
Responsible party
Sponsor
First posted
Jun 30, 2021
Start date
Mar 31, 2021
Primary completion
Dec 2026 (estimated)
Completion
May 2027 (estimated)
Last update
May 29, 2026

Study contacts

Chiara Azzari
principal investigator · Azienda Ospedaliero-Universitaria Ospedale Pediatrico Meyer - Italy

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Primary Immunodeficiency Diseases→

Other studies from this sponsor

Kedrion S.p.A.

Start the discussion